Cas:18977-45-2 1-Cyclopropyl-N-methylmethanamine manufacturer & supplier

We serve Chemical Name:1-Cyclopropyl-N-methylmethanamine CAS:18977-45-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

1-Cyclopropyl-N-methylmethanamine

Chemical Name:1-Cyclopropyl-N-methylmethanamine
CAS.NO:18977-45-2
Synonyms:(cyclopropylmethyl)(methyl)amine hydrochloride;1-cyclo-propyl-N-methylmethanamine;(Cyclopropylmethyl)methylamine;N-cyclopropylmethyl-N-methylamine;(N-methylaminomethyl)cyclopropane;1-Cyclopropyl-N-methylmethanamine;N-methyl-cyclopropylmethyl amine;Cyclopropanemethanamine, N-methyl-
Molecular Formula:C5H11N
Molecular Weight:85.147
HS Code:2921300090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:85.7±8.0 °C at 760 mmHg
Density:0.9±0.1 g/cm3
Index of Refraction:1.450
PSA:12.03000
Exact Mass:85.089149
LogP:0.47

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:


Contact us for information like (cyclopropylmethyl)(methyl)amine hydrochloride chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Cyclopropanemethanamine, N-methyl- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Cyclopropanemethanamine, N-methyl- Use and application,(Cyclopropylmethyl)methylamine technical grade,usp/ep/jp grade.


Related News: The company will see an immediate $6 billion bump to its topline thanks to Alexion’s C5 inhibitors, used to treat rare diseases like paroxysmal nocturnal hemoglobinuria. 2-Bromovinylidene-1,1,3-trimethyl-cyclohexane manufacturers Earlier this year, the US Food and Drug Administration approved Verquvo to reduce the risk of cardiovascular death and heart failure hospitalisation, following a hospitalisation for heart failure or need for outpatients intravenous (IV) diuretics in adults with symptomatic chronic heart failure and ejection fraction less than 45%. 6-benzoyl-2-(4-oxo-1,4-dihydroquinazolin-2-yl)-1H-phenalene-1,3(2H)-dione suppliers EMA said it considered that the results of the clinical studies used to support the application “were inconsistent and did not satisfactorily show that Nouryant was effective at reducing the ‘off’ time. Benzoyl chloride, 4-[2-(3-methylphenyl)ethoxy]- vendor & factory EMA said it considered that the results of the clinical studies used to support the application “were inconsistent and did not satisfactorily show that Nouryant was effective at reducing the ‘off’ time. ,A major advantage of identifying suitable biocatalysts early on is that it provides ample opportunity for optimization.